Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Transplant Cell Ther. 2023 Jun;29(6):394.e1-394.e7. doi: 10.1016/j.jtct.2023.03.011. Epub 2023 Mar 17.
Recent American Society for Transplantation and Cellular Therapy guidelines have sought to establish clinical and research expectations for participants in blood and marrow transplantation (BMT) and cellular therapy (CT) fellowships. However, little is known about participants in BMT/CT fellowships and the value they find from this additional training. We wanted to characterize the demographics, motivations, and experiences of recent participants in BMT/CT fellowships. We developed a 27-item online survey addressing backgrounds, application processes, training experiences, and perceived benefits among physicians who had started a clinical U.S.-based BMT/CT fellowship between 2012 to 2021. Anonymous responses were solicited through program director outreach, society website postings, targeted emails, and social media. Of 105 respondents (44% pediatric trainees), 4% were URMs and 39% were non-U.S. IMGs. The most important motivations for applying were comfort with allogeneic BMT, improved career prospects, and opportunities for research and publication. Almost all respondents (92%) attended donor selection meetings, whereas smaller proportions visited cell processing facilities (65%), HLA laboratories (57%), or good manufacturing practice facilities (22%). Most respondents reported ≥1 publication (26% reported 4+) based on research or experiences during their fellowship. Respondents reported improved post-fellowship comfort with all queried BMT/CT-related competencies. Seventy percent of respondents stated that they would recommend their fellowship highly to others; this corresponded to a Net Promoter Score of +65%, consistent with a strongly positive experience. Most respondents reported currently being in clinical practice (89% at academic centers), with a median of 70% of time currently spent caring for BMT/CT recipients. Although limited by recruitment methods and recall bias, our study demonstrated that BMT/CT fellowships are effective at increasing comfort with BMT/CT management and that most participants would highly recommend this BMT/CT training to others. Nevertheless, our study identified substantial heterogeneity in clinical responsibilities and BMT/CT-related laboratory exposure. The high representation of non-U.S. IMGs underscores the distinct role of BMT/CT fellowships for this group, whereas improved URM recruitment remains an important future direction for the field. Whether advanced fellowships will ever become required for the future BMT/CT workforce, analogous to the additional training required for solid organ transplantation in other medical and pediatric subspecialties, remains uncertain.
最近,美国移植和细胞治疗学会发布了指南,旨在为血液和骨髓移植(BMT)和细胞治疗(CT)研究员设定临床和研究期望。然而,人们对 BMT/CT 研究员的情况以及他们从这种额外培训中获得的价值知之甚少。我们希望描述 BMT/CT 研究员的人口统计学特征、动机和经验。我们开发了一个 27 项的在线调查,涵盖了在 2012 年至 2021 年间开始在美国临床 BMT/CT 研究员职位的医生的背景、申请流程、培训经验和感知收益。通过主任外联、学会网站发布、定向电子邮件和社交媒体征集匿名回复。在 105 名受访者(44%为儿科受训者)中,4%为 URM,39%为非美国 IMG。申请的最重要动机是对同种异体 BMT 的舒适感、改善职业前景以及研究和出版机会。几乎所有受访者(92%)都参加了供者选择会议,而参加细胞处理设施(65%)、HLA 实验室(57%)或良好生产实践设施(22%)的比例较小。大多数受访者报告根据其研究员期间的研究或经验发表了≥1 篇论文(26%报告了 4+)。受访者报告说,在研究员之后,他们对所有查询的 BMT/CT 相关能力更有信心。70%的受访者表示他们会强烈推荐他们的研究员;这对应于 65%的净推荐值,表明这是一次非常积极的经历。大多数受访者表示目前正在从事临床实践(89%在学术中心),目前 70%的时间用于照顾 BMT/CT 受者。尽管受到招聘方法和回忆偏差的限制,但我们的研究表明,BMT/CT 研究员能够有效提高对 BMT/CT 管理的信心,并且大多数参与者会强烈推荐其他人参加该 BMT/CT 培训。然而,我们的研究发现临床职责和 BMT/CT 相关实验室暴露存在很大的异质性。非美国 IMG 的高比例突出了 BMT/CT 研究员在该群体中的独特作用,而改善 URM 的招聘仍然是该领域的一个重要未来方向。是否需要高级研究员才能成为未来的 BMT/CT 劳动力,就像其他医学和儿科亚专业对实体器官移植所要求的那样,目前仍不确定。